{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:15:20Z","timestamp":1790381720448,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To analyze the clinical features and rate of metastatic disease in eyes with large (\u226510 mm thickness) uveal melanoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Retrospective noncomparative case series.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Participants:<\/jats:title>\n            <jats:p>There were 1,311 consecutive patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective medical chart review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main outcome measures:<\/jats:title>\n            <jats:p>Clinical features and rate of metastatic melanoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 1,311 patients with large melanoma, the mean age was 59 years (median 60, range 6\u201398 years) and 95% were white. Mean tumor basal dimension was 17 mm (median 17, range 7\u201325 mm), and mean tumor thickness was 12 mm (median 12, range 10\u201324 mm). Mean distance to the foveola was 6 mm (median 6, range 0\u201319 mm) and to optic nerve was 6 mm (median 5, range 0\u201319 mm). Of all eyes, using Kaplan\u2013Meier analysis, metastasis occurred in 11, 30, 45, and 52% at 1, 3, 5, and 7 years, respectively. According to tumor thickness (10.0\u201311.0, 11.1\u201312.0, 12.1\u201313.0, 13.1\u201314.0, 14.1\u201315.0, 15.1\u201316.0, and &gt;16.0 mm), metastasis at 1 year was found in 7, 12, 13, 15, 18, 22, and 20%; metastasis at 3 years was 24, 27, 37, 35, 51, 69, and 57%; metastasis at 5 years was 38%, 42%, 56%, 48%, 61%, not available, and 66%; and metastasis at 7 years was 47%, 47%, 61%, 57%, 61%, not available, and 66%. Clinical features associated with fewer metastatic events included Bruch membrane rupture (7-year metastasis at 48%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.018) and macular location (7-year metastasis at 32%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.014), whereas those with worse outcome included extraocular extension (7-year metastasis at 79%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). There was no significant difference in rate of melanoma-related metastasis for patients treated with plaque radiotherapy versus enucleation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Large uveal melanoma demonstrates 7-year rate of metastasis at 52%, with generalized increasing risk per 1-mm or 2-mm thickness increments. Extraocular extension was associated with greater metastatic rate, whereas Bruch membrane rupture and macular location demonstrated lower rate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002144","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T18:14:20Z","timestamp":1520619260000},"page":"2010-2022","source":"Crossref","is-referenced-by-count":20,"title":["LARGE UVEAL MELANOMA (\u226510 MM THICKNESS)"],"prefix":"10.1097","volume":"38","author":[{"given":"Carol L.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Sioufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin S.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Barna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell R.","family":"Harley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil Anthony T.","family":"Say","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Mashayekhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230817","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes","volume":"127","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R2-20230817","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ophtha.2014.08.046","article-title":"Management of posterior uveal melanoma. Past, present and future. The 2014 Charles L. Schepens Lecture","volume":"122","author":"Shields","year":"2015","journal-title":"Ophthalmology"},{"key":"R3-20230817","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jamaophthalmol.2014.77","article-title":"Age, survival predictors, and metastatic death in patients with choroidal melanoma. Tentative evidence of a therapeutic effect on survival","volume":"132","author":"Damato","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R4-20230817","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0161-6420(00)00150-0","article-title":"Stereotactic radiosurgery of large uveal melanomas with the gamma-knife","volume":"107","author":"Mueller","year":"2000","journal-title":"Ophthalmology"},{"key":"R5-20230817","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0360-3016(01)01560-7","article-title":"Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma","volume":"51","author":"Egger","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20230817","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0161-6420(02)01181-8","article-title":"Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients","volume":"109","author":"Shields","year":"2002","journal-title":"Ophthalmology"},{"key":"R7-20230817","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0161-6420(02)01273-3","article-title":"Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas","volume":"109","author":"Bechrakis","year":"2002","journal-title":"Ophthalmology"},{"key":"R8-20230817","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0161-6420(03)00661-4","article-title":"Iodine brachytherapy as an alternative to enucleation for large uveal melanomas","volume":"110","author":"Puusaari","year":"2003","journal-title":"Ophthalmology"},{"key":"R9-20230817","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0360-3016(02)04200-1","article-title":"Eye retention after proton beam radiotherapy for uveal melanoma","volume":"55","author":"Egger","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20230817","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ajo.2014.07.002","article-title":"Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma","volume":"158","author":"Mantel","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R11-20230817","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1167\/iovs.04-0066","article-title":"Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques","volume":"45","author":"Puusaari","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R12-20230817","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/archopht.124.6.838","article-title":"Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy","volume":"124","author":"Conway","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R13-20230817","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00417-006-0461-9","article-title":"Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height","volume":"245","author":"Puusaari","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-20230817","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/bjo.2009.162487","article-title":"Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate","volume":"94","author":"Bechrakis","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R15-20230817","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000334401","article-title":"Comparison of clinical outcomes for patients with large choroidal melanoma after primary treatment with enucleation or proton beam radiotherapy","volume":"227","author":"Mosci","year":"2012","journal-title":"Ophthalmologica"},{"key":"R16-20230817","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00417-012-2144-z","article-title":"Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma","volume":"251","author":"Sarici","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R17-20230817","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000433546","article-title":"Outcomes of proton beam radiotherapy for large non-peripapillary choroidal and ciliary body melanoma at TRIUMF and the BC cancer agency","volume":"2","author":"Weber","year":"2015","journal-title":"Ocul Oncol Pathol"},{"key":"R18-20230817","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CMR.0000000000000199","article-title":"Robotic radiosurgery for the treatment of medium and large uveal melanoma","volume":"26","author":"Eibl-Lindner","year":"2016","journal-title":"Melanoma Res"},{"key":"R19-20230817","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2016.12.026","article-title":"Cytogenetic abnormalities in uveal melanoma based on tumor features and size in 1059 patients. The 2016 W. Richard Green Lecture","volume":"124","author":"Shields","year":"2017","journal-title":"Ophthalmology"},{"key":"R20-20230817","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.ophtha.2017.04.003","article-title":"Personalized uveal melanoma prognosis based on cytogenetic profile in 1059 cases over an 8-year period. The 2017 Harry S. Gradle Lecture","volume":"124","author":"Shields","year":"2017","journal-title":"Ophthalmology"},{"key":"R21-20230817","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0002-9394(98)00039-7","article-title":"The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10","volume":"125","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"R22-20230817","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ajo.2004.07.006","article-title":"The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24","volume":"138","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R23-20230817","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0046-8177(82)80116-0","article-title":"Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis","volume":"13","author":"McLean","year":"1982","journal-title":"Hum Pathol"},{"key":"R24-20230817","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20230817","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"key":"R26-20230817","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/eye.2015.51","article-title":"Prognosis of uveal melanoma based on race in 8100 patients. The 2015 Doyne Lecture","volume":"29","author":"Shields","year":"2015","journal-title":"Eye"},{"key":"R27-20230817","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.ophtha.2013.03.012","article-title":"American Joint Committee on Cancer classification of uveal melanoma (tumor size category) predicts prognosis in 7731 patients","volume":"120","author":"Shields","year":"2013","journal-title":"Ophthalmology"},{"key":"R28-20230817","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ophtha.2015.01.026","article-title":"American Joint Committee on Cancer classification of uveal melanoma (anatomic stage) predicts prognosis in 7731 patients. The 2013 Zimmerman Lecture","volume":"122","author":"Shields","year":"2015","journal-title":"Ophthalmology"},{"key":"R29-20230817","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2014.5395","article-title":"International validation of the American Joint Committee on Cancer's 7th edition classification of uveal melanoma","volume":"133","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R30-20230817","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CMR.0b013e328358b373","article-title":"A pilot study of sunitinib malate in patients with metastatic uveal melanoma","volume":"22","author":"Mahipal","year":"2012","journal-title":"Melanoma Res"},{"key":"R31-20230817","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/13543784.2013.837449","article-title":"The potential role of sunitinib targeting melanomas","volume":"22","author":"Valsecchia","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"R32-20230817","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00347-015-0162-z","article-title":"Immunotherapy of uveal melanoma: vaccination against cancer. Muticenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma","volume":"112","author":"Schuler-Thurner","year":"2015","journal-title":"Ophthalmologe"},{"key":"R33-20230817","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-017-0606-5","article-title":"Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies","volume":"19","author":"Komatsubara","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"R34-20230817","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ophtha.2017.08.017","article-title":"Adjuvant sunitinib in high-risk patients with uveal melanoma. Comparison with institutional controls","volume":"125","author":"Valsecchi","year":"2018","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201810000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T01:21:25Z","timestamp":1692235285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201810000-00015"}},"subtitle":["Clinical Features and Millimeter-by-Millimeter Risk of Metastasis in 1311 Cases. The 2018 Albert E. Finley Lecture"],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002144","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}